GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $29.75 and traded as low as $26.67. GENMAB A/S/S shares last traded at $26.87, with a volume of 1,205,430 shares.
GENMAB A/S/S Stock Performance
The company has a 50-day moving average of $26.92 and a 200 day moving average of $29.75.
About GENMAB A/S/S
Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.
Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than GENMAB A/S/S
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
